Bitcoin (BTC) surged to $83,470 on October 22 but then fell back to $82,085 during a significant wave of short liquidations, the largest since October 2. This sharp market movement indicates increased volatility and active trading dynamics in the cryptocurrency market. Investors should watch for further price fluctuations as market reactions to liquidations continue.
Bitcoin's recent price surge and pullback provide context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Oct 24, 2026 01:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 43 rose and 6 fell today. Notable movers include LUNC (Terra Classic) at Rp0,841 with a 3.57% gain and a 76% buy order activity, YFI (Yearn) at Rp39.837.602 up 3.00% with 67% buy orders, and UNI (Uniswap) at Rp129.204 rising 2.60% but with a slight majority of sell orders at 52%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
